The Filing Desk

Intellia Therapeutics

NTLA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

NTLA · Last close · November 13, 2026
$9.70
Value Intellia Therapeutics yourself

Intellia Therapeutics' revenue rose 16.9% to $68 million in fiscal 2025. Its operating margin was −651.7%, up from −923.1% a year earlier. Free cash flow was −$396 million. The diluted share count rose 9.6%.

INTELLIA THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076550 Updated
Revenue
$68M
16.9%
Operating margin
−651.7%
271.4 pts
Net income
−$413M
 
Free cash flow
−$396M
 
Return on equity
−53.5%
0.5 pts
Market cap
$1.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Intellia Therapeutics does

Intellia Therapeutics develops gene-editing medicines based on CRISPR, a tool that can cut and change DNA. It has no approved product. Its approach is to deliver the editing tool into the body using lipid nanoparticles, tiny fat bubbles, and aim for a one-time treatment given by a single intravenous infusion in an outpatient setting.

Its two lead candidates are in Phase 3 trials. Lonvo-z is for hereditary angioedema, a rare inherited condition that causes swelling attacks, and the company is preparing for a planned launch in the first half of 2027. Nex-z is for transthyretin amyloidosis, a disease in which a misfolded protein builds up in organs. Intellia says these are the first in vivo genome editing candidates in Phase 3.

Intellia works with partners, mainly Regeneron, and licenses technology from others. It plans to build its own sales and manufacturing capability.

Its biggest risks, as it describes them

  • CRISPR gene editing has only recently been tested in people and may never lead to products it can sell.
  • Clinical development is long, costly and uncertain, and trials could show safety problems.
  • Negative public opinion and tighter regulation of gene editing could hurt it.
  • Its products may not be accepted by doctors, patients or insurers.
  • Patents of others or loss of licensed rights could hurt it.
From Intellia Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Intellia Therapeutics lost money in fiscal 2025: a net loss of $413 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments7491,193912602450
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio6.1x9.6x8.7x5.8x5.1x
Quick ratio6.1x9.6x8.7x5.8x5.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Intellia Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $1.4 million of Intellia Therapeutics shares on the open market, and 7 insiders sold $2.1 million, $1.2 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 21, 2026John M LeonardPresident and CEO, DirectorSold plan2,785$13.00$36,205Form 4
Aug 20, 2026John M LeonardPresident and CEO, DirectorSold plan19,890$12.60$250,614Form 4
Jul 22, 2026Edward J Dulac IIIEVP, Chief Financial OfficerSold8,111$11.25$91,249Form 4
Jul 2, 2026Edward J Dulac IIIEVP, Chief Financial OfficerSold plan4,677$18.00$84,186Form 4
Jul 1, 2026Michael P DubeVP, Chief Accounting OfficerSold2,641$16.78$44,316Form 4
Mar 2, 2026James BastaEVP, General CounselSold1,211$13.78$16,688Form 4
Mar 2, 2026Eliana ClarkEVP, Chief Technical OfficerSold607$13.78$8,364Form 4
Jan 5, 2026Fred E CohenDirectorBought150,000$9.35$1.4 millionForm 4
Jan 5, 2026John M LeonardPresident and CEO, DirectorSold34,146$9.21$314,485Form 4
Jan 5, 2026David LebwohlEVP, Chief Medical OfficerSold11,903$9.21$109,627Form 4
Jan 5, 2026James BastaEVP, General CounselSold10,397$9.21$95,756Form 4
Jan 5, 2026Eliana ClarkEVP, Chief Technical OfficerSold9,515$9.21$87,633Form 4
The latest 12 of 16 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−1,155.3%−553.2%−568.1%
Altman Z''2.03−3.19−6.12
Accruals ratio−6.2%−13.7%−1.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Intellia Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Intellia TherapeuticsFY2516.9%−651.7%−585.0%———
Vir BiotechnologyFY25−7.6%−699.2%−578.5%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
CytomX TherapeuticsFY25−44.8%−29.4%−99.5%———Compare
MeiraGTxFY25144.6%−130.2%−61.7%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue16263043583352365868
Revenue growth—58.5%16.5%41.6%34.5%−43.0%57.7%−30.4%59.5%16.9%
Gross profit——30435833————
Research and development326889108150230420435466389
Operating income−32−70−91−106−137−268−458−515−534−441
Net income−32−68−85−474−134−268−474−481−519−413
Diluted EPS (US$)−1.42−1.88−1.98−2.11−2.40−3.78−6.16−5.42−5.25−3.81
Diluted shares (millions)223643475671778999108
Cash flow
Cash from operations36−65−61−103−50−225−333−394−349−395
Capital expenditure61067413141461
Free cash flow30−75−68−110−54−238−347−408−355−396
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation715171520479113415480
Balance sheet at fiscal year end
Cash and short-term investments2733413142805977491,193912602450
Debt incl. finance leases——————————
Total assets2993763473346761,2941,5201,3011,191842
Total liabilities89766964149254284251319171
Shareholders' equity2103012782705271,0401,2361,050872671
Margins and ratios
Gross margin——100.0%100.0%100.0%100.0%————
Operating margin−195.2%−266.3%−298.6%−246.8%−235.5%−810.4%−879.0%−1,420.5%−923.1%−651.7%
Net margin−192.0%−258.6%−280.4%−1,100.1%−231.5%−810.5%−909.8%−1,326.5%−896.8%−609.9%
Free cash flow margin181.7%−288.6%−222.2%−255.3%−92.2%−719.4%−665.5%−1,124.9%−612.8%−585.0%
Rule of 40 (growth + FCF margin)—−230.1%−205.6%−213.7%−57.7%−762.4%−607.8%−1,155.3%−553.2%−568.1%
Return on capital——————————
Return on equity−33.5%−26.5%−29.5%−173.1%−33.7%−34.2%−41.7%−42.1%−54.0%−53.5%
Return on assets−16.6%−20.0%−23.6%−139.1%−26.6%−27.2%−33.7%−34.1%−41.7%−40.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Intellia Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Intellia Therapeutics.